The overall objective is to define the neuropsychological profile of patients with migraine and evaluate its association with: psychological outcome measures (anxiety-depressive symptoms, pain catastrophizing, excessive worry, and coping strategies); the clinical profile of migraine; the prodromal, ictal, or interictal phase of the migraine attack; pharmacological therapy; and detoxification treatment in patients with migraine associated with medication overuse headache.
Written informed consent.
Patients aged between 18 and 65 years.
Diagnosis of migraine according to the International Classification of Headache Disorders (ICHD-3) criteria.
Patients with a history of migraine for at least one year, to ensure the stability of the condition.
Severe medical or psychiatric conditions (depression, schizophrenia, psychosis) documented by specific previous diagnoses.
A history of alcohol or drug abuse.
Primary sensory deficits.
Patients aged between 18 and 65 years who suffer from migraines
Cohort
Cross-sectional
Not listed
Cognitive functioning
Neuropsychological test scores in migraine patients and proportion of participants with cognitive performance significantly different from age- and education-adjusted normative data.
Cognitive functions and psychological, clinical aspects
Correlation between cognitive performance scores and validated measures of anxiety/depression, pain catastrophizing, worry, coping strategies, headache-related impact and disability, and sleep quality in migraine patients.
Cognitive functions and different pharmacological treatments
Differences in cognitive test performance scores among groups of migraine patients receiving different pharmacological treatments
Cognitive functions and medication overuse headache
Change in cognitive test performance scores from pre-detoxification to post-detoxification treatment in patients with migraine and medication overuse headache.
Cognitive functions in the different phases of migraine
Comparison of cognitive test performance scores between ictal and interictal migraine phases and across different durations of disease.
Click on the lead sponsor to view all of their trials.
